Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus

被引：44

作者：

Bani-Sadr, F

Palmer, P

Scieux, C

Molina, JM

机构：

[1] Hosp St Louis, Serv Malad Infect & Trop, Paris, France

[2] Hosp St Louis, Virol Lab, Paris, France

来源：

CLINICAL INFECTIOUS DISEASES | 2004年 / 39卷 / 07期

关键词：

D O I：

10.1086/424012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir. The use of combination therapy with lamivudine and tenofovir for the treatment of HBV infection is very promising in the treatment of HIV/HBV coinfection.

引用

页码：1062 / 1064

页数：3

共 5 条

[1] Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. [J].